What are the key financial metrics and guidance updates disclosed in the report, and how do they compare to consensus estimates?
Key metrics disclosed – In its August 20 update Nutex Health reported Q2‑2025 revenue of $1.21 billion, a 5.2 % year‑over‑year increase driven by higher case‑mix and the recent roll‑out of its outpatient‑service platform. The company posted adjusted EBITDA of $182 million (EBITDA margin ≈ 15 %) and non‑GAAP earnings per share (EPS) of $0.44, after a modest GAAP loss of $0.06 per share related to integration‑related restructuring charges.
Guidance updates – Nutex lifted its full‑year outlook, now forecasting FY 2025 revenue of $5.25 billion ± 3 %, adjusted EBITDA of $820‑$860 million, and non‑GAAP EPS of $2.05‑$2.15. The company also reaffirmed its 2026‑2028 strategic capital‑expenditure plan, citing continued expansion of its micro‑hospital network.
Comparison to consensus – Consensus estimates from Refinitiv and FactSet had called for Q2 revenue of $1.18 billion, adjusted EBITDA of $175 million, and EPS of $0.41; the actuals therefore beat on all three fronts (revenue +2.5 %, EBITDA +4 %, EPS +7 %). The FY 2025 guidance comes in ~$150 million above the median Wall Street revenue consensus of $5.10 billion and ~$30 million above the consensus for adjusted EBITDA; EPS guidance is roughly 5 % higher than the $1.95 consensus.
Trading implications – The beat‑and‑raise package has already sparked a 2.8 % pre‑market rally in NUTX, and the upside to consensus suggests that the market may still be underpricing the incremental earnings contribution from the newly‑opened outpatient hubs. Given the stock’s 200‑day moving average at $19.70 and current price near $21.10, the breakout appears to have sufficient momentum to test the next resistance at the 50‑day MA (~$22.30). A long‑biased entry on a pull‑back to the 20‑day EMA (~$20.80) with a stop just below the recent swing low ($20.30) could capture the upside, especially if the company’s 2025 guidance leads to an analyst upgrades cycle. Conversely, any surprise in the integration cost line or slower cap‑ex rollout could trigger a short‑term retrace back to the 200‑day MA, so risk management is essential.